[Use of intravitreal bevacizumab for macular edema in branch retinal vein occlusion].
OBJECTIVE
To study the effect of intravitreal bevacizumab on macular edema secondary to branch retinal vein occlusion (BRVO).


METHODS
6 eyes of 5 patients averaging 70 years, who had received either retinal photocoagulation or trans-tenon retrobulbar triamcinolone injections or both, but in whom the macular edema remained. There was an average of 337 days from BRVO onset to injection of bevacizumab. Corrected vision and foveal thickness were measured.


RESULTS
Visual acuity and foveal thickness improved significantly one month after injection.


CONCLUSIONS
Intravitreal injection of bevacizumab is effective for a short time.
Yamauchi
Yukihide
Y
Eguchi Eye Hospital, Japan. himawari@jim.u-ryukyu.ac.jp
Mori
Fumihiko
F
Masahara
Hidetaka
H
Kameda
Yusuke
Y
Suzuki
Michiro
M
Mori
Yosai
Y
Eguchi
Shuichiro
S
D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012170:Retinal Vein Occlusion / Q000150:complications*; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab